Literature DB >> 16864989

Effect of 15d-PGJ2 on the expression of CD40 and RANTES induced by IFN-gamma and TNF-alpha on renal tubular epithelial cells (HK-2).

Ya Jie Zhang1, Xiao Yang, Qing Yu Kong, Yun Fang Zhang, Wei Ying Chen, Xiu Qing Dong, Xiao Yan Li, Xue Qing Yu.   

Abstract

BACKGROUND/AIMS: Recent evidence shows that peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ameliorates a variety of inflammatory conditions. CD40 is a co-stimulatory molecule and its ligation induces production of different proinflammatory cytokines including RANTES (regulated upon activation, normal T cell expressed), which are considered as important factors in the initiation and maintenance of inflammatory response. The aim of this study was to investigate the effect of PPAR-gamma on CD40 and RANTES production on cultured human renal proximal tubular epithelial (HK-2) cells.
METHODS: HK-2 cells were maintained under defined in vitro conditions and treated with either PPAR-gamma agonist 15-deoxy-12,14-prostaglandin J2 (15d-PGJ2) or 15d-PGJ2 + PPAR-gamma antagonist GW9662, and then stimulated with a combination of tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma). The CD40 and RANTES levels were investigated.
RESULTS: HK-2 cells expressed low levels of CD40 and RANTES. Activation of HK-2 cells by combined treatment of TNF-alpha and IFN-gamma results in strong synergistic effects on the expression of CD40 and the secretion of RANTES. 15d-PGJ2 significantly decreased CD40 and RANTES expression and GW9662 partly abrogated the inhibition of 15d-PGJ2 on CD40 and RANTES.
CONCLUSION: 15d-PGJ2 significantly decreased CD40 and RANTES expression in HK-2 cells, which were partially mediated by PPAR-gamma-dependent pathways. These results point to PPAR-gamma as a remarkable new target in the prevention of tubular inflammatory injury associated with renal disease. Copyright (c) 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16864989     DOI: 10.1159/000094735

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  7 in total

1.  Rosiglitazone, a Peroxisome Proliferator-Activated Receptor (PPAR)-γ Agonist, Attenuates Inflammation Via NF-κB Inhibition in Lipopolysaccharide-Induced Peritonitis.

Authors:  Yun-Fang Zhang; Xun-Liang Zou; Jun Wu; Xue-Qing Yu; Xiao Yang
Journal:  Inflammation       Date:  2015-12       Impact factor: 4.092

Review 2.  The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies.

Authors:  P C Manoria; H K Chopra; S K Parashar; A L Dutta; Brian Pinto; Ajit Mullasari; Samir Prajapati
Journal:  Indian Heart J       Date:  2013-11-25

3.  TNF-α promotes IFN-γ-induced CD40 expression and antigen process in Myb-transformed hematological cells.

Authors:  Wenyi Gu; Jiezhong Chen; Lei Yang; Kong-Nan Zhao
Journal:  ScientificWorldJournal       Date:  2012-04-01

4.  Immunoregulatory mechanisms of macrophage PPAR-γ in mice with experimental inflammatory bowel disease.

Authors:  R Hontecillas; W T Horne; M Climent; A J Guri; C Evans; Y Zhang; B W Sobral; J Bassaganya-Riera
Journal:  Mucosal Immunol       Date:  2010-11-10       Impact factor: 7.313

5.  15-Deoxy-Δ12,14-prostaglandin J2 Exerts Antioxidant Effects While Exacerbating Inflammation in Mice Subjected to Ureteral Obstruction.

Authors:  Line Nilsson; Fredrik Palm; Rikke Nørregaard
Journal:  Mediators Inflamm       Date:  2017-04-19       Impact factor: 4.711

6.  SUMOylation of PPARγ by rosiglitazone prevents LPS-induced NCoR degradation mediating down regulation of chemokines expression in renal proximal tubular cells.

Authors:  Ying Lu; Qiao Zhou; Yongbing Shi; Jian Liu; Fang Zhong; Xu Hao; Cong Li; Nan Chen; Weiming Wang
Journal:  PLoS One       Date:  2013-11-08       Impact factor: 3.240

Review 7.  Peroxisome proliferator-activated receptor agonists modulate neuropathic pain: a link to chemokines?

Authors:  Caroline M Freitag; Richard J Miller
Journal:  Front Cell Neurosci       Date:  2014-08-20       Impact factor: 5.505

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.